THE INVENTION PROVIDES ANTIBODIES THAT SPECIFICALLY BIND TO KALLIDIN OR DES-ARG10-KALLIDIN. THE INVENTION ALSO PROVIDES PHARMACEUTICAL COMPOSITIONS, AS WELL AS NUCLEIC ACIDS ENCODING ANTI-KALLIDIN OR DES-ARG10-KALLIDIN ANTIBODIES, RECOMBINANT EXPRESSION VECTORS AND HOST CELLS FOR MAKING SUCH ANTIBODIES, OR FRAGMENTS THEREOF. METHODS OF USING ANTIBODIES OF THE INVENTION TO MODULATE KALLIDIN OR DES-ARG10-KALLIDIN ACTIVITY OR DETECT KALLIDIN OR DES-ARG10-KALLIDIN OR, EITHER IN VITRO OR IN VIVO, ARE ALSO PROVIDED BY THE INVENTION. THE INVENTION FURTHER PROVIDES METHODS OF MAKING ANTIBODIES THAT SPECIFICALLY BIND TO DES-ARG₉-BRADYKININ AND DES-ARG₁₀-KALLIDIN-LIKE PEPTIDE.
